BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors
Science Advances · 04.10.2024 · 10 (40)
DOI: 10.1126/sciadv.ado7120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 04.10.2024. Verfasst von Andrew S Judd und 44 weiteren Autor:innen. Beteiligte Einrichtung: AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL 60064, USA. Hauptthemen laut MEDLINE: bcl-X Protein, Immunoconjugates, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Overexpression of the antiapoptotic protein B-cell lymphoma-extra large (BCL-X L ) is associated with drug resistance and disease progression in numerous cancers. The compelling nature of this protein as a therapeutic target prompted efforts to develop selective small-molecule BCL-X L inhibitors. Although efficacious in preclinical models, we report herein that selective BCL-X L inhibitors cause severe mechanism-based cardiovascular toxicity in higher preclinical species. To overcome this liability, antibody-drug conjugates were constructed using altered BCL-X L –targeting warheads, unique linker technologies, and therapeutic antibodies. The epidermal growth factor receptor–targeting antibody-drug conjugate AM1-15 inhibited growth of tumor xenografts and did not cause cardiovascular toxicity nor dose-limiting thrombocytopenia in monkeys. While an unprecedented BCL-X L –mediated toxicity was uncovered in monkey kidneys upon repeat dosing of AM1-15, this toxicity was mitigated via further drug-linker modification to afford AM1-AAA (AM1-25). The AAA drug-linker has since been incorporated into mirzotamab clezutoclax, the first selective BCL-X L –targeting agent to enter human clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL 60064, USA.
ORCID-Profile: Andrew S Judd, Bhupinder Bawa, Wayne R Buck, Zhi-Fu Tao, Yingchun Li, George Doherty, Kenneth R Durbin, Robin Frey, Deanna Haasch, Sandra Haman, Anthony R Haight, James Holms, Russell A Judge, Gary J Jenkins, Ruth L Martin, Diya Mitra, Scott Mittelstadt, Lorne Nelson, Paul Nimmer, Joann Palma, Richard Peterson, Sherry L Ralston, Xiaoqiang Shen, Kedar S Vaidya, Jin Wang, Xinxin Zhang, Eric A Blomme, John C Kalvass, Andrew Phillips, Andrew J Souers
Zitieren
APA
Judd, A. S., Bawa, B., Buck, W. R., Tao, Z. F., Li, Y., Mitten, M. J., Bruncko, M., Catron, N., Doherty, G., Durbin, K. R., Enright, B., Frey, R., Haasch, D., Haman, S., Haight, A. R., Henriques, T. A., Holms, J., Izeradjene, K., Judge, R. A., …, & Souers, A. J. (2024). BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Science Advances, 10(40). https://doi.org/10.1126/sciadv.ado7120
Vancouver
Judd AS, Bawa B, Buck WR, Tao ZF, Li Y, Mitten MJ, et al. BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Science Advances. 2024;10(40). doi:10.1126/sciadv.ado7120
BibTeX
@article{Judd2024,
author = {Judd, Andrew S and Bawa, Bhupinder and Buck, Wayne R and Tao, Zhi-Fu and Li, Yingchun and Mitten, Michael J and Bruncko, Milan and Catron, Nathaniel and Doherty, George and Durbin, Kenneth R and Enright, Brian and Frey, Robin and Haasch, Deanna and Haman, Sandra and Haight, Anthony R and Henriques, Tracy A and Holms, James and Izeradjene, Kamel and Judge, Russell A and Jenkins, Gary J and Kunzer, Aaron and Leverson, Joel D and Martin, Ruth L and Mitra, Diya and Mittelstadt, Scott and Nelson, Lorne and Nimmer, Paul and Palma, Joann and Peterson, Richard and Phillips, Darren C and Ralston, Sherry L and Rosenberg, Saul H and Shen, Xiaoqiang and Song, Xiaohong and Vaidya, Kedar S and Wang, Xilu and Wang, Jin and Xiao, Yu and Zhang, Haichao and Zhang, Xinxin and Blomme, Eric A and Boghaert, Erwin R and Kalvass, John C and Phillips, Andrew and Souers, Andrew J},
title = {BCL-X L –targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {40},
doi = {10.1126/sciadv.ado7120}
}
EUVIMED